Multiple myeloma

Cancer
Favicons?domain=wwwCentre Daily Times | November 02, 2009

Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2010

ARRY-520 - KSP inhibitor for AML and MM: Array continued a Phase 1 trial of ARRY-520, a novel KSP inhibitor, in patients with solid tumors and two Phase 1/2 trials in patients with acute myelogenous leukemia and multiple myeloma.

In this article: Cancer, Revenue, Gemcitabine, Capecitabine, ErbB2, Glucose, and Docetaxel

Connections-toggle
Filter by
or